<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Early molecular relapse detection &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/early-molecular-relapse-detection/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 09:18:52 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Early molecular relapse detection &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Personalized Liquid Biopsy Advances CNS Tumor Care</title>
		<link>https://bioengineer.org/personalized-liquid-biopsy-advances-cns-tumor-care/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 23 Aug 2025 11:10:42 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Circulating tumor DNA sensitivity]]></category>
		<category><![CDATA[Early molecular relapse detection]]></category>
		<category><![CDATA[Genomic assay for cancer monitoring]]></category>
		<category><![CDATA[Pediatric CNS tumors]]></category>
		<category><![CDATA[Personalized liquid biopsy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/personalized-liquid-biopsy-advances-cns-tumor-care/</guid>

					<description><![CDATA[In a groundbreaking advancement poised to revolutionize pediatric oncology, researchers have unveiled a highly personalized liquid biopsy assay designed to track central nervous system (CNS) tumors in children with unprecedented sensitivity. The study, published in the upcoming 2025 volume of BMC Cancer, introduces MRD4U, a bespoke genomic assay aimed at revolutionizing the early detection of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">257133</post-id>	</item>
	</channel>
</rss>
